Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B
US10941113B2 · kind B2 · utility
1Cited by
80References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 12, 2018 |
| Grant date | Mar 9, 2021 |
| Priority date | — |
| Expiry date | Nov 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C317/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R1, R2, R3 and R4 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.